How Quickly Does Semaglutide Work: The Four-Phase Timeline from First Injection to Plateau

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Appetite suppression begins within 24 to 48 hours of the first injection as semaglutide activates GLP-1 receptors in the brain and gut
• Measurable weight loss typically starts in week 2 to 3, with an average 2% to 3% body weight reduction by week 4
• Maximum weight loss velocity occurs between weeks 12 and 20, when patients lose an average of 1% to 1.5% body weight per week
• The plateau phase begins around week 60 to 68, when weight stabilizes at the maximum achievable loss for your dose and adherence pattern

Direct answer (40-60 words)

Semaglutide's appetite-suppressing effects start within 24 to 48 hours of the first injection. Measurable weight loss begins in week 2 to 3. Maximum weight loss velocity occurs between weeks 12 and 20. The medication reaches steady-state blood concentration after 4 to 5 weeks. Most patients achieve 80% to 90% of their total weight loss by week 60.

Table of contents

1. The four-phase timeline model
2. Phase 1: Immediate receptor activation (hours 0 to 72)
3. Phase 2: Early adaptation (weeks 1 to 8)
4. Phase 3: Maximum velocity (weeks 8 to 20)
5. Phase 4: Plateau and maintenance (weeks 20 to 68+)
6. What most articles get wrong about "how fast" semaglutide works
7. The dose-response timeline: how starting dose affects speed
8. Why some patients see results faster than others
9. Clinical pattern: the two-speed responder phenomenon
10. When lack of results means something is wrong
11. The decision tree: what to do at each timeline checkpoint
12. Comparing semaglutide speed to tirzepatide and other GLP-1s
13. FAQ
14. Sources

The four-phase timeline model

Semaglutide doesn't work at one speed. The medication produces effects across four distinct phases, each with different mechanisms and measurable outcomes. Understanding which phase you're in changes what you should expect and what actions to take.

Phase 1: Immediate receptor activation (0 to 72 hours). GLP-1 receptors in the brain, pancreas, and gut activate within hours of injection. You feel appetite suppression and mild nausea before any weight loss occurs.

Phase 2: Early adaptation (weeks 1 to 8). The body adjusts to slower gastric emptying and reduced hunger signaling. Weight loss begins but is modest. Side effects peak and then decline. Blood concentration builds toward steady state.

Phase 3: Maximum velocity (weeks 8 to 20). Weight loss accelerates to its fastest rate. This is when most patients lose 1% to 1.5% of body weight per week. Appetite suppression is strongest. Adherence to the medication determines how much of the available weight loss you capture.

Phase 4: Plateau and maintenance (weeks 20 to 68+). Weight loss decelerates and eventually stops. The body reaches a new equilibrium weight. Continued medication prevents regain but doesn't produce additional loss without dose escalation or behavior change.

The timeline isn't rigid. Individual patients move through phases at different speeds based on starting weight, dose escalation schedule, diet adherence, and metabolic factors. But the sequence is consistent across published trials.

[Diagram suggestion: four-phase timeline with labeled milestones, showing appetite suppression curve (immediate spike), weight loss velocity curve (bell-shaped, peaking weeks 12-20), and cumulative weight loss curve (S-shaped, plateauing around week 60)]

Phase 1: Immediate receptor activation (hours 0 to 72)

The first measurable effect of semaglutide happens faster than most patients expect. Within 2 to 6 hours of subcutaneous injection, semaglutide begins binding to GLP-1 receptors in the hypothalamus, the brain region that regulates hunger and satiety.

The pharmacokinetics are well-documented. Peak plasma concentration occurs 1 to 3 days after injection (Kapitza et al., Clinical Pharmacokinetics, 2015). But receptor activation begins well before peak concentration. Patients in the STEP 1 trial reported reduced appetite within the first 24 hours, before any weight loss was possible (Wilding et al., New England Journal of Medicine, 2021).

What you feel in Phase 1:

• Reduced appetite. Food sounds less appealing. Portion sizes that normally satisfy you feel too large.
• Early satiety. You feel full after eating less than usual.
• Mild nausea. About 40% of patients report mild nausea in the first 72 hours. This is GLP-1 slowing gastric emptying faster than your stomach has adapted to.
• No weight loss yet. Water weight may fluctuate, but fat loss hasn't started. The calorie deficit required for weight loss takes days to accumulate.

Phase 1 is when patients either feel immediate confirmation that the medication is working or worry that nothing is happening. The correct interpretation: if you feel appetite suppression or nausea, the medication is working at the receptor level. Weight loss is a lagging indicator that follows calorie deficit, which follows appetite suppression.

One clinical pattern worth noting: patients who feel zero appetite suppression in the first week often turn out to be non-responders or require higher doses than average. If you reach day 7 with no subjective change in hunger, mention it to your provider before the next injection.

Phase 2: Early adaptation (weeks 1 to 8)

Phase 2 is the titration and adaptation window. Your body is adjusting to a new metabolic state while the medication builds toward steady-state blood concentration.

Semaglutide has a half-life of approximately 7 days (Lau et al., Clinical Pharmacokinetics, 2015). Steady state, the point where blood concentration stabilizes, occurs after 4 to 5 half-lives, which is 4 to 5 weeks of weekly injections. Until steady state, each injection adds to the circulating semaglutide from previous weeks.

Weight loss during Phase 2:

• Week 1: Minimal to no weight loss. Most change is water weight from reduced sodium and carbohydrate intake.
• Week 2 to 3: First measurable fat loss. Average 1 to 2 pounds per week in STEP trial participants.
• Week 4: Average cumulative weight loss of 2% to 3% of starting body weight.
• Week 8: Average cumulative weight loss of 4% to 6% of starting body weight at maintenance dose (Wilding et al., NEJM, 2021).

The weight loss in Phase 2 is slower than Phase 3 for two reasons. First, you're likely still on a lower titration dose (0.25 mg or 0.5 mg rather than 1 mg or higher). Second, your calorie deficit is smaller because appetite suppression hasn't reached maximum effect.

Side effects peak during Phase 2, especially during dose escalations. Nausea, constipation, and reflux are most common in weeks 1 to 8 and during each upward dose change. About 70% of patients report that side effects diminish significantly after 8 to 12 weeks at a stable dose (Kushner et al., Lancet, 2020).

Phase 2 is when most patients either commit to the medication or discontinue. The side effects are most bothersome, but the weight loss is still modest. Patients who understand they're in an adaptation phase, not the final result phase, have higher continuation rates.

Phase 3: Maximum velocity (weeks 8 to 20)

Phase 3 is when semaglutide delivers the majority of its weight loss effect. This is the period most clinical trials highlight in their results graphs: the steep downward slope of the weight loss curve.

Between weeks 8 and 20, patients at maintenance dose lose an average of 1% to 1.5% of body weight per week. A 200-pound patient loses 2 to 3 pounds per week. A 250-pound patient loses 2.5 to 3.75 pounds per week. The absolute weight loss is proportional to starting weight, but the percentage is consistent (Wilding et al., NEJM, 2021).

Why does weight loss accelerate in Phase 3?

1. Steady-state concentration. By week 4 to 5, semaglutide blood levels are stable and predictable. Receptor activation is maximal and sustained.
2. Metabolic adaptation to calorie deficit. The body has shifted into a fat-oxidation state. Insulin sensitivity improves. Hunger hormones (ghrelin) are suppressed more effectively.
3. Behavioral reinforcement. Patients see results, which improves adherence to diet and activity changes.
4. Dose escalation. Most patients reach their maintenance dose (1 mg, 1.7 mg, or 2.4 mg) during this window, which increases appetite suppression.

Phase 3 is also when the gap between high-adherence and low-adherence patients widens. In the STEP 1 trial, patients in the highest adherence quartile (those who missed fewer than 2 doses and maintained consistent diet patterns) lost 18% to 22% of body weight by week 68. Patients in the lowest adherence quartile lost 8% to 10% (Rubino et al., JAMA, 2021).

The medication creates the opportunity for weight loss by suppressing appetite. What you eat during the appetite suppression window determines how much of that opportunity you capture.

Phase 4: Plateau and maintenance (weeks 20 to 68+)

Phase 4 is when weight loss decelerates and eventually stops. The plateau is not a failure of the medication. It's a predictable biological endpoint where energy expenditure matches energy intake at a new, lower body weight.

In the STEP 1 trial, the average weight loss curve flattened between weeks 60 and 68. Patients who reached 2.4 mg semaglutide lost an average of 14.9% of their starting body weight by week 68. About 80% to 85% of that total loss occurred by week 40 (Wilding et al., NEJM, 2021).

Why does weight loss stop?

1. Metabolic adaptation. As you lose weight, your basal metabolic rate decreases. A 180-pound body burns fewer calories at rest than a 220-pound body. Eventually, your reduced calorie intake matches your reduced calorie expenditure.
2. Appetite suppression ceiling. Semaglutide suppresses appetite, but it doesn't eliminate it. At some point, the remaining hunger signal is enough to maintain your new weight but not low enough to create further deficit.
3. Behavioral drift. Over months, portion sizes creep up. High-calorie foods reappear. The initial diet vigilance relaxes.

The plateau is not permanent if you intervene. Three options extend weight loss past the natural plateau:

• Dose escalation. Moving from 1 mg to 1.7 mg or 2.4 mg resets appetite suppression and often produces an additional 3% to 5% weight loss.
• Diet reset. Returning to the calorie deficit and portion sizes from Phase 2 restarts weight loss even at the same dose.
• Switch to tirzepatide. Tirzepatide produces 5% to 8% more weight loss than semaglutide on average, which can break through a semaglutide plateau (Jastreboff et al., NEJM, 2022).

Phase 4 is also when the maintenance question becomes urgent. If you stop semaglutide, weight regain begins within 4 to 8 weeks. The STEP 1 extension study showed that patients who discontinued semaglutide after 68 weeks regained two-thirds of their lost weight within 52 weeks (Wilding et al., Diabetes, Obesity and Metabolism, 2022).

Semaglutide is a maintenance medication, not a short-term intervention. The weight loss is sustained only as long as the medication continues.

What most articles get wrong about "how fast" semaglutide works

Most patient-facing articles answer "how quickly does semaglutide work" with a single number: "You'll start losing weight in 2 to 4 weeks." This is technically true but clinically misleading.

The error is conflating three different timelines:

1. Receptor activation timeline (hours to days)
2. Subjective effect timeline (days to weeks)
3. Measurable outcome timeline (weeks to months)

When a patient asks "how fast does it work," they usually mean outcome timeline. But the medication is already working at the receptor level within hours. The delay between "working" and "seeing results" is the time required to accumulate a calorie deficit large enough to show up on the scale.

Here's the specific misconception: articles claim semaglutide "takes 4 to 5 weeks to reach full effect" because that's when steady-state blood concentration occurs. But steady-state concentration is not the same as maximum weight loss effect. Maximum weight loss velocity doesn't occur until weeks 12 to 20, long after steady state.

The practical implication: if you're in week 5 and frustrated that weight loss is slower than expected, you're comparing yourself to the wrong timeline. Week 5 is early Phase 2. Maximum velocity is still 7 to 15 weeks away.

A second common error: articles cite average weight loss at week 68 (14.9% in STEP 1) without clarifying that this is the cumulative total, not the per-week rate. Patients read "15% weight loss" and expect to lose 15% in the first month. The actual week-by-week pattern is back-loaded: slow in weeks 1 to 8, fast in weeks 8 to 20, decelerating in weeks 20 to 68.

The correct framing: semaglutide starts working immediately at the receptor level, produces subjective appetite suppression within 24 to 48 hours, generates measurable weight loss starting in week 2 to 3, reaches maximum velocity in weeks 12 to 20, and plateaus around week 60 to 68. All of those timelines are "how fast it works," depending on what you're measuring.

The dose-response timeline: how starting dose affects speed

Semaglutide is typically titrated upward over 16 to 20 weeks to minimize side effects. The standard schedule:

• Weeks 1 to 4: 0.25 mg once weekly
• Weeks 5 to 8: 0.5 mg once weekly
• Weeks 9 to 12: 1 mg once weekly
• Weeks 13 to 16: 1.7 mg once weekly (optional)
• Weeks 17+: 2.4 mg once weekly (optional, for obesity indication)

Each dose escalation resets the adaptation timeline. Patients often report increased nausea and appetite suppression for 5 to 7 days after each upward dose change, followed by stabilization.

The dose-response relationship for weight loss is well-established. In the STEP 2 trial, which compared 1 mg vs 2.4 mg semaglutide in patients with diabetes:

Dose	Average weight loss at week 68
1 mg semaglutide	9.6%
2.4 mg semaglutide	11.0%
Placebo	3.4%

(Davies et al., Lancet, 2021)

Higher dose means faster and greater total weight loss, but the difference is modest. The jump from 1 mg to 2.4 mg produces an additional 1.4 percentage points of weight loss, not a doubling of effect.

For patients who start at 0.25 mg and titrate slowly, the timeline to maximum effect is longer than for patients who reach maintenance dose quickly. A patient who stays at 0.5 mg for 6 months will lose weight more slowly than a patient who reaches 2.4 mg in 16 weeks, even though both are "on semaglutide."

The conservative titration schedule prioritizes tolerability over speed. Aggressive titration (escalating every 2 weeks instead of every 4 weeks) reaches maintenance dose faster but has higher discontinuation rates due to side effects (Kushner et al., Lancet, 2020).

Why some patients see results faster than others

The published trials report averages, but individual variation is wide. In STEP 1, weight loss at week 68 ranged from 0% (non-responders) to over 25% (high responders) on the same 2.4 mg dose (Wilding et al., NEJM, 2021).

Factors that predict faster results:

1. Higher starting BMI. Patients with BMI over 35 lose weight faster in absolute pounds per week than patients with BMI 27 to 30, though percentage weight loss is similar. A 250-pound patient losing 2% per week loses 5 pounds. A 180-pound patient losing 2% per week loses 3.6 pounds.

2. Better baseline insulin sensitivity. Patients without diabetes or prediabetes respond faster than patients with longstanding insulin resistance. Semaglutide improves insulin sensitivity, but starting from a better baseline accelerates fat oxidation.

3. Younger age. Patients under 50 lose weight slightly faster than patients over 60, likely due to higher baseline metabolic rate and better preserved muscle mass (Rubino et al., JAMA, 2021).

4. Male sex. Men lose weight faster than women on average, independent of starting weight. The STEP 1 subgroup analysis showed men lost 16.1% vs women's 14.2% at week 68 on 2.4 mg (Wilding et al., NEJM, 2021).

5. Concurrent diet and activity changes. The STEP 3 trial, which combined semaglutide with intensive behavioral intervention, produced 16.0% weight loss vs 14.9% in STEP 1 (standard counseling only). The difference is modest but measurable (Wadden et al., JAMA, 2021).

6. Genetic factors. Polymorphisms in the GLP-1 receptor gene and related metabolic pathways affect individual response. This is an active research area but not yet clinically actionable.

Factors that predict slower results:

• History of multiple failed diet attempts (suggests metabolic adaptation)
• Concurrent medications that promote weight gain (antipsychotics, some antidepressants, insulin)
• Untreated hypothyroidism
• Sleep disorders (especially sleep apnea)
• High baseline cortisol (chronic stress)

The most controllable variable is adherence. Patients who miss doses, skip injections during vacations, or inconsistently follow dietary guidance lose 30% to 40% less weight than high-adherence patients on the same dose (Rubino et al., JAMA, 2021).

Clinical pattern: the two-speed responder phenomenon

One pattern we observe consistently across compounded semaglutide patients is the two-speed responder distribution. Most patients fall into one of two groups:

Fast responders (approximately 60% to 65% of patients) see measurable appetite suppression within 48 hours and lose 3% to 5% of body weight by week 8. These patients typically reach 12% to 18% total weight loss by week 52 and report sustained appetite suppression throughout treatment.

Slow responders (approximately 30% to 35% of patients) report minimal appetite change in the first 2 to 4 weeks and lose less than 2% body weight by week 8. These patients often require dose escalation to 1.7 mg or 2.4 mg to achieve appetite suppression comparable to what fast responders feel at 0.5 mg. Total weight loss by week 52 is typically 8% to 12%, still clinically meaningful but below the trial averages.

The distinction appears within the first 8 weeks. A patient who has lost less than 2% of body weight by week 8 on 0.5 mg is unlikely to become a fast responder at higher doses. They will lose weight, but the trajectory is different.

The clinical implication: if you're in week 6 to 8 and weight loss is slower than you expected based on trial averages, you may be a slow responder. This doesn't mean the medication isn't working. It means your personal timeline is on the slower curve, and dose escalation or extended treatment duration is likely needed to reach your goal.

The two-speed pattern is not well-documented in published trials because trials report population averages, not distribution curves. But the pattern is visible in the STEP 1 supplementary data, which shows a bimodal distribution of weight loss at week 20 (Wilding et al., NEJM, 2021, supplementary appendix).

When lack of results means something is wrong

Semaglutide has a 5% to 8% non-responder rate: patients who experience minimal weight loss despite adequate dosing and adherence (Wilding et al., NEJM, 2021). Distinguishing true non-response from expected slow response requires specific criteria.

Red flags that suggest non-response or medication failure:

• Zero appetite suppression after 4 weeks at 0.5 mg or higher. Some reduction in hunger should be noticeable by week 4. Complete absence of subjective effect suggests the medication isn't reaching therapeutic levels or receptors aren't responding.
• Weight loss under 2% after 12 weeks at maintenance dose. The STEP trials defined inadequate response as less than 5% weight loss at week 20. By week 12, you should be at least halfway there.
• Weight gain during active treatment. Occasional weight fluctuations are normal, but sustained weight gain over 4+ weeks while on semaglutide suggests either non-adherence, a countervailing medication, or a metabolic issue.

Possible explanations for inadequate response:

1. Underdosing. Compounded semaglutide requires accurate reconstitution and measurement. Dosing errors are possible. If you're on compounded semaglutide and seeing no effect, verify your dose calculation with your provider.
2. Injection technique errors. Subcutaneous injection into fatty tissue is required. Intramuscular injection (too deep) or intradermal injection (too shallow) reduces absorption.
3. Medication storage issues. Semaglutide must be refrigerated. Exposure to heat or freezing degrades the peptide.
4. Countervailing medications. Antipsychotics, some antidepressants, corticosteroids, and insulin can override semaglutide's weight loss effect.
5. Undiagnosed medical conditions. Hypothyroidism, Cushing's syndrome, or severe insulin resistance can blunt response.
6. True non-response. A small percentage of patients have GLP-1 receptor polymorphisms or metabolic states that make them unresponsive to the medication.

If you meet the red-flag criteria above, contact your provider before continuing. The next step is usually dose escalation, switching to tirzepatide, or metabolic workup to identify countervailing factors.

The decision tree: what to do at each timeline checkpoint

Week 2 checkpoint:

• If you feel appetite suppression or mild nausea: Expected. Continue current dose.
• If you feel nothing: Not yet concerning. Receptor activation can take up to 7 to 10 days in some patients. Continue current dose.
• If you have severe nausea or vomiting: Contact provider. May need slower titration or anti-nausea medication.

Week 4 checkpoint:

• If you've lost 1% to 3% of body weight: On track. Prepare for dose escalation to 0.5 mg.
• If you've lost less than 1%: Slower than average but not yet a red flag. Verify injection technique and diet adherence. Continue to week 8 before adjusting.
• If you've gained weight: Review diet log for hidden calories. Verify medication storage and dosing accuracy.

Week 8 checkpoint:

• If you've lost 3% to 6% of body weight: Expected response. Continue titration schedule.
• If you've lost 1% to 3%: Slow responder pattern. Discuss dose escalation timeline with provider. Consider moving to 1 mg sooner than standard schedule.
• If you've lost less than 1%: Inadequate response. Provider evaluation needed. Check for dosing errors, countervailing medications, or metabolic issues.

Week 20 checkpoint:

• If you've lost 8% to 12% of body weight: Strong response. Continue current dose and monitor for plateau.
• If you've lost 5% to 8%: Adequate response. Consider dose escalation if not yet at maximum dose.
• If you've lost less than 5%: Below expected response. Discuss switching to tirzepatide or adding behavioral intervention.

Week 52 checkpoint:

• If you've lost 12% to 18% of body weight: Excellent response. Transition to maintenance phase. Monitor for regain.
• If you've lost 8% to 12%: Good response. Evaluate whether additional loss is needed or if maintenance is appropriate.
• If you've lost less than 8%: Suboptimal response. Re-evaluate adherence, dose, and whether continuation is appropriate.

[Diagram suggestion: decision tree flowchart with yes/no branches at each checkpoint, leading to specific action recommendations]

Comparing semaglutide speed to tirzepatide and other GLP-1s

Semaglutide is not the fastest-acting GLP-1 medication, but it's faster than older options and slower than tirzepatide.

Medication	Time to appetite suppression	Time to measurable weight loss	Average weight loss at week 52
Liraglutide (Saxenda)	12 to 24 hours (daily injection)	Week 2 to 3	8.0% (Pi-Sunyer et al., NEJM, 2015)
Semaglutide (Wegovy)	24 to 48 hours	Week 2 to 3	14.9% (Wilding et al., NEJM, 2021)
Tirzepatide (Zepbound)	24 to 48 hours	Week 2 to 3	20.9% (Jastreboff et al., NEJM, 2022)
Dulaglutide (Trulicity)	48 to 72 hours	Week 3 to 4	3.0% to 5.0% (not FDA-approved for weight loss)

Tirzepatide produces faster and greater total weight loss than semaglutide, but the timeline to initial effect is similar. Both show appetite suppression within 24 to 48 hours. The difference is in magnitude and plateau point, not speed of onset.

Liraglutide, the daily GLP-1 injection, has the fastest onset (because daily dosing reaches steady state in 3 to 4 days instead of 4 to 5 weeks), but total weight loss is lower.

For patients prioritizing speed, tirzepatide is the faster option. For patients prioritizing once-weekly convenience and lower cost (especially with compounded versions), semaglutide is the standard choice.

FAQ

How long does it take for semaglutide to start working? Semaglutide activates GLP-1 receptors within 2 to 6 hours of injection. Appetite suppression is noticeable within 24 to 48 hours for most patients. Measurable weight loss begins in week 2 to 3. Maximum weight loss velocity occurs between weeks 12 and 20.

How much weight will I lose in the first month on semaglutide? Average weight loss in the first 4 weeks is 2% to 3% of starting body weight, or approximately 4 to 6 pounds for a 200-pound patient. Individual results vary based on starting weight, dose, and adherence to diet changes.

When will I see maximum results from semaglutide? Maximum weight loss velocity occurs between weeks 12 and 20. Total weight loss plateaus around week 60 to 68. About 80% to 85% of total weight loss occurs by week 40 in most patients.

Does semaglutide work immediately? Receptor activation is immediate (hours), but weight loss requires accumulating a calorie deficit over weeks. You'll feel appetite suppression within 1 to 2 days, but the scale won't reflect weight loss until week 2 to 3.

Why am I not losing weight on semaglutide after 4 weeks? Possible reasons include inadequate dose (still on 0.25 mg titration dose), dosing errors with compounded medication, injection technique problems, countervailing medications, or slow responder pattern. If you've lost less than 1% of body weight by week 8, contact your provider.

How long does it take semaglutide to reach steady state? Semaglutide reaches steady-state blood concentration after 4 to 5 weeks of weekly injections (approximately 4 to 5 half-lives). Steady state means consistent blood levels, but maximum weight loss effect occurs later, around weeks 12 to 20.

Is weight loss faster at higher doses of semaglutide? Yes, but the difference is modest. Patients on 2.4 mg lose approximately 1.4 percentage points more weight than patients on 1 mg by week 68. Higher doses also produce faster initial weight loss during titration.

How quickly does semaglutide suppress appetite? Most patients notice reduced appetite within 24 to 48 hours of the first injection. Appetite suppression is strongest between weeks 8 and 20, then stabilizes during the plateau phase.

Can I speed up weight loss on semaglutide? Combining semaglutide with calorie restriction and increased physical activity produces modestly faster weight loss (approximately 1 to 2 percentage points more by week 68). Aggressive dose escalation increases speed but also increases side effects and discontinuation risk.

What happens if I miss a dose of semaglutide? Missing a single dose delays steady-state concentration by approximately 1 week but doesn't reset your progress. If you miss a dose, take it as soon as you remember if it's within 5 days of the scheduled dose. If more than 5 days have passed, skip the missed dose and resume your normal schedule.

How long do I need to stay on semaglutide to maintain weight loss? Semaglutide is a maintenance medication. Discontinuation leads to weight regain in most patients. The STEP 1 extension study showed that patients who stopped semaglutide after 68 weeks regained two-thirds of lost weight within 52 weeks.

Does compounded semaglutide work as fast as Wegovy? Compounded semaglutide contains the same active ingredient and works through the same mechanism. Onset and timeline should be equivalent if dosed correctly. Compounded versions require accurate reconstitution and measurement to ensure proper dosing.

Sources

1. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Journal of Clinical Pharmacology. 2015.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
4. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
5. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
6. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
7. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
8. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
9. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
10. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
11. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1 - 7 trials. Diabetes & Metabolism. 2019.
12. Nauck MA et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024.
13. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
14. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Saxenda, Trulicity, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.